NCT02865135View on ClinicalTrials.gov

Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

March 30, 2017

Primary Completion Date

October 4, 2019

Study Completion Date

February 6, 2023

Conditions
Cancer of Head and NeckCancer of CervixCancer of Anus
Interventions
DRUG

DPX-E7 vaccine

Therapeutic vaccine for the treatment of incurable HPV16-related oropharyngeal, cervical and anal cancer in HLA-A\*02 positive patients.

DRUG

Cyclophosphamide

Cyclophosphamide is a medication primarily used in the management and treatment of neoplasms, including multiple myeloma, sarcoma, and breast cancer. Cyclophosphamide is a nitrogen mustard that exerts its anti-neoplastic effects through alkylation.

Trial Locations (1)

02215

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Stand Up To Cancer

OTHER

lead

Dana-Farber Cancer Institute

OTHER

NCT02865135 - Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer | Biotech Hunter | Biotech Hunter